新型冠状病毒肺炎中的直接口服抗凝剂：用还是不用？ - Suppr

Suppr

超能文献

DOAC in COVID-19: Yes or No?

作者信息

Schutgens Roger E

机构信息

Benign Hematology Center, Van Creveldkliniek, University Medical Center Utrecht, University Utrecht, The Netherlands.

出版信息

Hemasphere. 2020 Dec 29;5(1):e526. doi: 10.1097/HS9.0000000000000526. eCollection 2021 Jan.

DOI:10.1097/HS9.0000000000000526

PMID:33403357

原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC7773328/

Abstract

摘要

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/6675/7773328/acb2ab4262fd/hs9-5-e526-g001.jpg

相似文献

DOAC in COVID-19: Yes or No?新型冠状病毒肺炎中的直接口服抗凝剂：用还是不用？

Hemasphere. 2020 Dec 29;5(1):e526. doi: 10.1097/HS9.0000000000000526. eCollection 2021 Jan.

Prior use of anticoagulation is associated with a better survival in COVID-19.先前使用抗凝剂与 COVID-19 患者的更好生存相关。

J Thromb Thrombolysis. 2021 Nov;52(4):1207-1211. doi: 10.1007/s11239-021-02486-4. Epub 2021 Jun 1.

Use of and Satisfaction with Telemedicine Services during the Pandemic: Findings from the COVID-19 Snapshot Monitoring in Germany (COSMO).疫情期间远程医疗服务的使用情况及满意度：来自德国COVID-19快速监测（COSMO）的结果

Healthcare (Basel). 2022 Jan 4;10(1):92. doi: 10.3390/healthcare10010092.

[Direct oral anticoagulant associated bleeding].[直接口服抗凝剂相关出血]

J Mal Vasc. 2016 Jul;41(4):272-8. doi: 10.1016/j.jmv.2016.05.008. Epub 2016 Jun 11.

Predictors of Direct Oral Anticoagulants Utilization for Thromboembolism Prevention in Atrial Fibrillation.用于心房颤动血栓栓塞预防的直接口服抗凝剂使用的预测因素。

J Pharm Pharm Sci. 2017;20:8-14. doi: 10.18433/J30W4F.

Continuous and minimally-interrupted direct oral anticoagulant are both safe compared with vitamin K antagonist for atrial fibrillation ablation: An updated meta-analysis.与维生素 K 拮抗剂相比，直接口服抗凝药持续和最小中断给药用于房颤消融均安全：一项更新的荟萃分析。

Int J Cardiol. 2018 Jul 1;262:51-56. doi: 10.1016/j.ijcard.2018.03.095. Epub 2018 Mar 21.

Structure and lateral interaction in mixed monolayers of dioctadecyldimethylammonium chloride (DOAC) and stearyl alcohol.双十八烷基二甲基氯化铵（DOAC）与硬脂醇混合单层膜的结构和横向相互作用。

Langmuir. 2013 May 7;29(18):5407-17. doi: 10.1021/la400143k. Epub 2013 Apr 22.

Clinical impact of direct oral anticoagulant measuring in a real-life setting.真实环境中直接口服抗凝剂检测的临床影响。

Thromb Res. 2019 Mar;175:40-45. doi: 10.1016/j.thromres.2019.01.016. Epub 2019 Jan 24.

Simple method for removing DOACs from plasma samples.从血浆样本中去除 DOACs 的简单方法。

Thromb Res. 2018 Mar;163:117-122. doi: 10.1016/j.thromres.2018.01.047. Epub 2018 Jan 31.

Impending rupture of abdominal aortic aneurysm due to apixaban use.使用阿哌沙班导致腹主动脉瘤即将破裂。

J Cardiol Cases. 2020 Nov 24;23(5):221-223. doi: 10.1016/j.jccase.2020.11.011. eCollection 2021 May.

引用本文的文献

Anticoagulant therapy in COVID-19: A narrative review.新型冠状病毒肺炎的抗凝治疗：叙述性综述。

Clin Transl Sci. 2023 Sep;16(9):1510-1525. doi: 10.1111/cts.13569. Epub 2023 Jun 30.

Edoxaban Versus Low-Molecular-Weight Heparin in Hospitalized COVID-19 Patients With Atrial Fibrillation.依度沙班与低分子肝素在 COVID-19 合并心房颤动住院患者中的比较。

Clin Appl Thromb Hemost. 2023 Jan-Dec;29:10760296231180865. doi: 10.1177/10760296231180865.

Efficacy and Safety of Anticoagulant Therapy in COVID-19-Related Pulmonary Embolism with Different Extension.不同范围的新型冠状病毒肺炎相关肺栓塞抗凝治疗的疗效和安全性

Biomedicines. 2023 Apr 26;11(5):1282. doi: 10.3390/biomedicines11051282.

Lung perfusion assessed by SPECT/CT after a minimum of three months anticoagulation therapy in patients with SARS-CoV-2-associated acute pulmonary embolism: a retrospective observational study.在 SARS-CoV-2 相关急性肺栓塞患者接受至少三个月抗凝治疗后，通过 SPECT/CT 评估肺灌注：一项回顾性观察研究。

Respir Res. 2022 Oct 31;23(1):296. doi: 10.1186/s12931-022-02188-2.

Renal, cardiac, neurological, cutaneous and coagulopathic long-term manifestations of COVID-19 after recovery; A review.新冠康复后出现的肾脏、心脏、神经、皮肤和凝血功能长期并发症；综述。

Epidemiol Infect. 2022 Sep 21;150:e208. doi: 10.1017/S0950268822001480.

Thromboprophylaxis with standard-dose vs. flexible-dose heparin for hospitalized COVID-19 patients: a target trial emulation.COVID-19 住院患者中标准剂量与灵活剂量肝素预防血栓：一项目标试验模拟。

J Clin Epidemiol. 2022 Nov;151:96-103. doi: 10.1016/j.jclinepi.2022.08.006. Epub 2022 Aug 18.

Good practice statements for antithrombotic therapy in the management of COVID-19: Guidance from the SSC of the ISTH.COVID-19 管理中的抗血栓治疗良好实践声明：ISTH 的 SSC 指南。

J Thromb Haemost. 2022 Oct;20(10):2226-2236. doi: 10.1111/jth.15809. Epub 2022 Jul 29.

The role of direct oral anticoagulants in the era of COVID-19: are antiviral therapy and pharmacogenetics limiting factors?直接口服抗凝剂在 COVID-19 时代的作用：抗病毒治疗和药物遗传学是限制因素吗？

Croat Med J. 2022 Jun 22;63(3):287-294. doi: 10.3325/cmj.2022.63.287.

COVID-19 Coagulopathy: From Pathogenesis to Treatment.COVID-19 凝血功能障碍：从发病机制到治疗。

Acta Haematol. 2022;145(3):282-296. doi: 10.1159/000522498. Epub 2022 Feb 8.

Dabigatran in patients with atrial fibrillation after COVID-19 hospitalization: an update of the ANIBAL protocol.新冠病毒肺炎住院后房颤患者使用达比加群：ANIBAL方案的更新

Drugs Context. 2022 Jan 24;11. doi: 10.7573/dic.2021-9-4. eCollection 2022.

本文引用的文献

Diagnosis, Management, and Pathophysiology of Arterial and Venous Thrombosis in COVID-19.新型冠状病毒肺炎中动脉和静脉血栓形成的诊断、管理及病理生理学

JAMA. 2020 Dec 22;324(24):2548-2549. doi: 10.1001/jama.2020.23422.

Anticoagulation in COVID-19: Effect of Enoxaparin, Heparin, and Apixaban on Mortality.COVID-19 中的抗凝治疗：依诺肝素、肝素和阿哌沙班对死亡率的影响。

Thromb Haemost. 2020 Dec;120(12):1691-1699. doi: 10.1055/s-0040-1720978. Epub 2020 Nov 13.

Dabigatran, the oral anticoagulant of choice at discharge in patients with non-valvular atrial fibrillation and COVID-19 infection: the ANIBAL protocol.达比加群，非瓣膜性心房颤动合并新型冠状病毒肺炎感染患者出院时的口服抗凝药首选：ANIBAL方案。

Drugs Context. 2020 Sep 18;9. doi: 10.7573/dic.2020-8-3. eCollection 2020.

Comparison of published guidelines for management of coagulopathy and thrombosis in critically ill patients with COVID 19: implications for clinical practice and future investigations.比较发表的指南，以管理凝血病和血栓形成在危重病患者与 COVID-19：对临床实践和未来的调查的影响。

Crit Care. 2020 Sep 16;24(1):559. doi: 10.1186/s13054-020-03273-y.

ISTH DIC subcommittee communication on anticoagulation in COVID-19.ISTH DIC 小组委员会关于 COVID-19 抗凝治疗的沟通。

J Thromb Haemost. 2020 Sep;18(9):2138-2144. doi: 10.1111/jth.15004.

Cytochrome P450-mediated drug interactions in COVID-19 patients: Current findings and possible mechanisms.细胞色素 P450 介导的 COVID-19 患者药物相互作用：当前发现和可能的机制。

Med Hypotheses. 2020 Nov;144:110033. doi: 10.1016/j.mehy.2020.110033. Epub 2020 Jun 26.

COVID-19 and Renal Failure: Challenges in the Delivery of Renal Replacement Therapy.2019冠状病毒病与肾衰竭：肾脏替代治疗实施中的挑战

J Clin Med Res. 2020 May;12(5):276-285. doi: 10.14740/jocmr4160. Epub 2020 May 8.

Coagulation abnormalities and thrombosis in patients with COVID-19.新型冠状病毒肺炎患者的凝血异常与血栓形成

Lancet Haematol. 2020 Jun;7(6):e438-e440. doi: 10.1016/S2352-3026(20)30145-9. Epub 2020 May 11.

Direct oral anticoagulant plasma levels' striking increase in severe COVID-19 respiratory syndrome patients treated with antiviral agents: The Cremona experience.严重 COVID-19 呼吸综合征患者接受抗病毒药物治疗后直接口服抗凝剂血浆水平显著升高：克雷莫纳经验。

J Thromb Haemost. 2020 Jun;18(6):1320-1323. doi: 10.1111/jth.14871. Epub 2020 May 6.

Switch from oral anticoagulants to parenteral heparin in SARS-CoV-2 hospitalized patients.在 SARS-CoV-2 住院患者中，将口服抗凝剂转换为普通肝素。

Intern Emerg Med. 2020 Aug;15(5):751-753. doi: 10.1007/s11739-020-02331-1. Epub 2020 Apr 15.

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验